Gina Tomaine

News

FDA Approves Brentuximab Vedotin Plus Chemotherapy for Pediatric Patients With Classical Hodgkin Lymphoma

11/17/2022

The FDA granted approval to brentuximab vedotin in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide for pediatric patients 2 years of age and older with previously untreated high-risk classical Hodgkin...

The FDA granted approval to...

11/17/2022

Oncology

News

Tacrolimus and Reduced-Dose Methotrexate Combined With Mycophenolate Mofetil to Prevent Graft-Versus-Host Disease

09/28/2023

Gina Tomaine ;

Tacrolimus plus a reduced-dose of methotrexate combined with mycophenolate for GVHD prevention demonstrated a more favorable toxicity profile compared with the standard-of-care, according to a phase 3 trial.

Tacrolimus plus a reduced-dose...

09/28/2023

Oncology

News

First-Line Brentuximab Vedotin Lowers Risk of Death in Classical Hodgkin Lymphoma: ECHELON-1

08/17/2022

Gina Tomaine ;

For patients with classical Hodgkin lymphoma, first-line treatment with brentuximab vedotin plus AVD resulted in a significantly lower risk of death by 41% vs standard ABVD at 6 years, according to results from the ECHELON-1 trial.

For patients with classical...

08/17/2022

Oncology

News

FDA Approves Zanubrutinib for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

01/20/2023

Gina Tomaine ;

On January 19, 2023, the FDA approved zanubrutinib for chronic lymphocytic leukemia or small lymphocytic lymphoma.

On January 19, 2023, the FDA...

01/20/2023

Oncology

News

Bendamustine Demonstrates Safety, Efficacy for Lymphodepletion Before Tisagenlecleucel in R/R Large B-Cell Lymphoma

09/30/2022

Gina Tomaine ;

Bendamustine is an effective lymphodepletion regimen before tisagenlecleucel in patients with refractory/relapsed large B-cell lymphomas, according to a recent study.

Bendamustine is an effective...

09/30/2022

Oncology

News

Bevacizumab Biosimilar Candidate TAB008 Comparable to Reference Bevacizumab for Patients With Locally Advanced, Metastatic EGFR Wild-Type Non-Squamous NSCLC

07/10/2023

Gina Tomaine ;

In a phase 3 study, biosimilar candidate TAB008 was found to be similar to reference bevacizumab in terms of efficacy and safety for patients with locally advanced, metastatic EGFR wild-type non-squamous non-small cell lung cancer.

In a phase 3 study, biosimilar...

07/10/2023

Oncology

News

Mosunetuzumab Demonstrates Safety, Efficacy in Patients With Relapsed/Refractory Follicular Lymphoma

11/17/2022

Gina Tomaine ;

CD20-CD3 bispecific antibody mosunetuzumab demonstrated a favorable safety profile and induced high rates of complete remission in patients with relapsed/refractory follicular lymphoma, according to a phase 2 study.

CD20-CD3 bispecific antibody...

11/17/2022

Oncology

Natalizumab Plus Corticosteroid Regimen Ineffective in Improving Outcomes for Newly Diagnosed High-Risk GI GVHD

09/28/2023

Gina Tomaine ;

A regimen of natalizumab combined with corticosteroids was generally well-tolerated but did not improve outcomes for patients with newly diagnosed high-risk GI GVHD, according to a phase 2 study.

A regimen of natalizumab...

09/28/2023

Oncology

News

Treatment Regimen Using Non–Anthracycline-Containing Backbone is Effective for Older Patients With AML

08/19/2022

Gina Tomaine ;

Venetoclax added to cladribine and low-dose cytarabine alternating with venetoclax and 5-azacitidine demonstrated efficacy among older or unfit patients with newly diagnosed AML, according to results from a phase 2 trial.

Venetoclax added to cladribine...

08/19/2022

Oncology

News

FDA Approves Teclistamab for Patients With Relapsed/Refractory MM

10/27/2022

Gina Tomaine ;

The FDA granted accelerated approval to teclistamab for the treatment of adult patients with relapsed or refractory MM who received ≥4 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38...

The FDA granted accelerated...

10/27/2022

Oncology